Dr. Gil Shamai and Prof. Ron Kimmel, from the Faculty's Geometric Image Processing Laboratory, have developed a model that can estimate the risk of breast cancer recurrence and the expected benefit from chemotherapy. The model is based on advanced artificial intelligence with clinical expertise. This is an innovative tool that may bring personalized medicine closer to the field, and offer patients a more accurate, faster, and more accessible solution. This is the first artificial intelligence model of its kind that has been verified as being able to predict the benefit of breast cancer treatment based on pathological samples.
The study was published this week in the prestigious scientific journal The Lancet Oncology and was also presented at the European Society for Medical Oncology (ESMO) conference. The model was developed in interfaculty, interdisciplinary and international collaboration with physicians, biologists and pathologists from the Technion and leading institutions around the world.
To the article at the link
To the journal at the link
[Back to the news index]